367 completed, 88 terminated, 35 active not recruiting, 26 withdrawn. 566 Phase 2, 88 Phase 1, 14 Phase 3.
Follow Amgen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | University of Alberta | 80 | 2027-01-02 | 2026-08-12 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-12-01 | 2026-11-09 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD Inebilizumab - Immunoglobulin G4-related Disease | Phase 2 | Recruiting | Amgen | 15 | 2026-10-21 | 2026-11-16 |
| LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan Xaluritamig - Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer | Phase 2 | Not yet recruiting | Thomas Jefferson University | 30 | 2026-10-01 | 2026-08-14 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) Inebilizumab - Generalized Myasthenia Gravis | Phase 2 | Recruiting | Amgen | 15 | 2026-07-21 | 2026-10-23 |
| Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes Romosozumab, Alendronate (Fosamax), Placebo Romosozumab - Osteoporosis, Post-menopausal | Phase 2 | Withdrawn | University of Pittsburgh | 2026-06-20 | 2026-06-04 | |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease AMG 732 - Thyroid Eye Disease | Phase 2 | Recruiting | Amgen | 30 | 2026-05-07 | 2026-07-23 |
| Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia Blinatumomab - Phase 2 Study, Blinatumomab | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2026-04-21 | 2026-11-12 |
| A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 Tarlatamab - Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | ETOP IBCSG Partners Foundation | 48 | 2026-04-15 | 2026-09-21 |
| Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma | Phase 2 | Recruiting | Asrar Alahmadi | 39 | 2026-03-20 | 2026-07-06 |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight Maridebart cafraglutide, Placebo - Overweight or Obesity and Elevated Liver Fat | Phase 2 | Active not recruiting | Amgen | 180 | 2026-03-05 | 2026-09-28 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) Subcutaneous Blinatumomab - CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL) | Phase 2 | Recruiting | West Virginia University | 78 | 2026-01-15 | 2026-04-13 |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation Sotorasib, Panitumumab - Advanced Solid Tumors | Phase 2 | Recruiting | Amgen | 14 | 2026-01-02 | 2026-07-23 |
| Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) Tarlatamab - Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | Phase 2 | Recruiting | National Taiwan University Hospital | 32 | 2026-01-01 | 2026-09-17 |
| Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab Tarlatamab, standard of care second-line chemotherapy (FOLFIRI) - Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin | Phase 2 | Terminated | Grupo Espanol de Tumores Neuroendocrinos | 1 | 2025-12-18 | 2026-09-18 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Amgen | 104 | 2025-12-08 | 2026-10-05 |
| Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors Tarlatamab, Temozolomide (TMZ) - Glioma, CNS Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Centre Leon Berard | 70 | 2025-11-04 | 2026-09-14 |
Showing 20 of 566. Sign in to see all of them.
Multiple Myeloma (52) · Neoplasms (44) · Colorectal Neoplasms (38) · Breast Neoplasms (34) · Carcinoma, Non-Small-Cell Lung (31) · Neoplasm Metastasis (26) · Anemia (19) · Recurrence (18) · Arthritis, Rheumatoid (16) · Colonic Neoplasms (16) · Lymphoma, Non-Hodgkin (16) · Lung Neoplasms (15) · Lymphoma (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Rectal Neoplasms (14)
Panitumumab (74) · carfilzomib (42) · Dexamethasone (41) · Denosumab (33) · blinatumomab (31) · pegfilgrastim (27) · Darbepoetin alfa (24) · Carboplatin (23) · Paclitaxel (23) · Cisplatin (21) · Cyclophosphamide (20) · romiplostim (20) · Fluorouracil (19) · Irinotecan (19) · Lenalidomide (18)
United States (313) · Spain (85) · Germany (81) · Canada (80) · France (78) · Poland (60) · United Kingdom (56) · Italy (55) · Australia (51) · Belgium (48) · Netherlands (46) · Czechia (38) · Japan (36) · Greece (34) · Denmark (33)
John Rieth, MD (3) · Antonio Arrivi, MD (2) · Aram Hezel, MD (2) · Benjamin Derman, MD (2) · Elias Jabbour, MD (2) · Elizabeth Shane, MD (2) · Heinz Ludwig, MD (2) · Jaime Feliu, MD (2) · James R Berenson, MD (2) · Joan Maurel, MD (2)
PMID 41671463, PMID 24144944, PMID 34928306, PMID 37316690, PMID 20838998, PMID 22070868, PMID 22961727, PMID 23986513, PMID 24014831, PMID 27789188, PMID 32079690, PMID 33051459, PMID 34213592, PMID 34301173, PMID 35314069, PMID 35820631, PMID 37491104, PMID 38979716, PMID 39097160, PMID 40780143, PMID 12481149, PMID 12675312, PMID 12957457, PMID 13680158, PMID 14770445, PMID 15173079, PMID 15210739, PMID 15352656, PMID 15522938, PMID 15860486, PMID 15909591, PMID 15911237, PMID 15983958, PMID 16200343, PMID 16381629, PMID 16411031, PMID 16495394, PMID 16530701, PMID 16786120, PMID 16899365, PMID 17289537, PMID 17602062, PMID 17664336, PMID 17671985, PMID 17699221, PMID 17705175, PMID 17708711, PMID 17785764, PMID 17962619, PMID 18195176
2014 (9), 2016 (9), 2023 (9), 2017 (8), 2019 (7), 2008 (5), 2009 (5), 2015 (5), 2018 (3), 2025 (3), M01RR001032 (2), R01DK058785 (2), 1UF1AG046150-01 (1), 2004 (1), 2005 (1)